Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.63 USD
Change Today -0.035 / -2.10%
Volume 723.8K
ONTY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

oncothyreon inc (ONTY) Snapshot

Open
$1.65
Previous Close
$1.67
Day High
$1.66
Day Low
$1.58
52 Week High
07/23/14 - $3.60
52 Week Low
02/6/15 - $1.48
Market Cap
166.8M
Average Volume 10 Days
872.2K
EPS TTM
$-0.62
Shares Outstanding
102.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOTHYREON INC (ONTY)

oncothyreon inc (ONTY) Related Businessweek News

No Related Businessweek News Found

oncothyreon inc (ONTY) Details

Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

49 Employees
Last Reported Date: 03/10/15
Founded in 1985

oncothyreon inc (ONTY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $276.0K
Chief Operating Officer
Total Annual Compensation: $310.0K
Chief Medical Officer
Total Annual Compensation: $355.5K
Chief Scientific Officer
Total Annual Compensation: $270.5K
Compensation as of Fiscal Year 2014.

oncothyreon inc (ONTY) Key Developments

Oncothyreon Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Oncothyreon Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. Net loss for the year ended December 31, 2014 was $50.0 million, or $0.64 per basic and diluted share, compared with a net loss of $38.8 million, or $0.62 per basic and diluted share, for the comparable period in 2013. The increase in net loss was due to higher research and development expenses, primarily as a result of an increase of $10.0 million in license fees paid to Array. The increase in net loss was also the result of higher general and administrative expenses and lower non-cash income from the change in fair value of warrant liability, which was $0.8 million for the year ended December 31, 2014 compared to $2.3 million for the year ended December 31, 2013. Loss from operations was $50.835 million against $41.223 million a year ago. Net loss for the three months ended December 31, 2014 was $27.6 million, or $0.30 per basic and diluted share, compared with a net loss of $6.4 million, or $0.09 per basic and diluted share, for the comparable period in 2013. The increase in net loss for the three months ended December 31, 2014 compared to the prior year period was primarily attributable to an upfront payment of $20.0 million to Array in December 2014 and lower non-cash income from the change in the fair value of warrant liability, which was $0.3 million for the three months ended December 31, 2014 compared to $1.2 million for the three months ended December 31, 2013. Loss from operations was $27.858 million against $7.583 million a year ago. The company currently expects operating expenses in 2015 to be lower than in 2014, which included the upfront payment to Array for the exclusive license to ONT-380. The company currently expects cash used in operations in 2015 to be approximately $35.0 - $38.0 million.

Oncothyreon Inc. Announces Appointment of Steven P. James to its Board of Directors

Oncothyreon Inc. announced the appointment of Steven P. James to its board of directors. Mr. James served as President and Chief Executive Officer of Labrys Biologics Inc., from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014.

Oncothyreon Inc, Q4 2014 Earnings Call, Mar 10, 2015

Oncothyreon Inc, Q4 2014 Earnings Call, Mar 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $1.63 USD -0.035

ONTY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTY.
View Industry Companies
 

Industry Analysis

ONTY

Industry Average

Valuation ONTY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOTHYREON INC, please visit www.oncothyreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.